These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 31066232)
1. Sodium tanshinone IIA sulfonate prevents the adverse left ventricular remodelling: Focus on polymorphonuclear neutrophil-derived granule components. Mao S; Taylor S; Chen Q; Zhang M; Hinek A J Cell Mol Med; 2019 Jul; 23(7):4592-4600. PubMed ID: 31066232 [TBL] [Abstract][Full Text] [Related]
2. Rationale and Design of Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction (STAMP-REMODELING) Trial: A Randomized Controlled Study. Mao S; Li X; Wang L; Yang PC; Zhang M Cardiovasc Drugs Ther; 2015 Dec; 29(6):535-542. PubMed ID: 26482376 [TBL] [Abstract][Full Text] [Related]
4. Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. Rao SV; Zeymer U; Douglas PS; Al-Khalidi H; White JA; Liu J; Levy H; Guetta V; Gibson CM; Tanguay JF; Vermeersch P; Roncalli J; Kasprzak JD; Henry TD; Frey N; Kracoff O; Traverse JH; Chew DP; Lopez-Sendon J; Heyrman R; Krucoff MW J Am Coll Cardiol; 2016 Aug; 68(7):715-23. PubMed ID: 27515331 [TBL] [Abstract][Full Text] [Related]
5. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Cerisano G; Buonamici P; Valenti R; Sciagrà R; Raspanti S; Santini A; Carrabba N; Dovellini EV; Romito R; Pupi A; Colonna P; Antoniucci D Eur Heart J; 2014 Jan; 35(3):184-91. PubMed ID: 24104875 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of early cardiac magnetic resonance imaging functional and geometric indexes for adverse left ventricular remodelling in patients with anterior ST-segment elevation myocardial infarction: A report from the CIRCUS study. Pezel T; Besseyre des Horts T; Schaaf M; Croisille P; Bière L; Garcia-Dorado D; Jossan C; Roubille F; Cung TT; Prunier F; Meyer E; Amaz C; Derumeaux G; de Poli F; Hovasse T; Gilard M; Bergerot C; Thibault H; Ovize M; Mewton N Arch Cardiovasc Dis; 2020 Nov; 113(11):710-720. PubMed ID: 33160891 [TBL] [Abstract][Full Text] [Related]
7. Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice. Gao S; Li L; Li L; Ni J; Guo R; Mao J; Fan G J Mol Cell Cardiol; 2019 Dec; 137():59-70. PubMed ID: 31629735 [TBL] [Abstract][Full Text] [Related]
8. Association between discharge heart rate and left ventricular adverse remodelling in ST segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Joyce E; Hoogslag GE; Leong DP; Fox K; Schalij MJ; Marsan NA; Bax JJ; Delgado V Heart; 2013 Apr; 99(8):556-61. PubMed ID: 23468514 [TBL] [Abstract][Full Text] [Related]
9. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. Duengen HD; Kim RJ; Zahger D; Orvin K; Kornowski R; Admon D; Kettner J; Shimony A; Otto C; Becka M; Kanefendt F; Romo AI; Hasin T; Ostadal P; Rojas GC; Senni M; Am Heart J; 2020 Jun; 224():129-137. PubMed ID: 32375104 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. Rao SV; Zeymer U; Douglas PS; Al-Khalidi H; Liu J; Gibson CM; Harrison RW; Joseph DS; Heyrman R; Krucoff MW Am Heart J; 2015 Nov; 170(5):929-37. PubMed ID: 26542501 [TBL] [Abstract][Full Text] [Related]
11. Prognosis-based definition of left ventricular remodeling after ST-elevation myocardial infarction. Reindl M; Reinstadler SJ; Tiller C; Feistritzer HJ; Kofler M; Brix A; Mayr A; Klug G; Metzler B Eur Radiol; 2019 May; 29(5):2330-2339. PubMed ID: 30547201 [TBL] [Abstract][Full Text] [Related]
12. Design and rationale of a multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the effect of vitamin D on ventricular remodelling in patients with anterior myocardial infarction: the VITamin D in Acute Myocardial Infarction (VITDAMI) trial. Tuñón J; González-Hernández I; Llanos-Jiménez L; Alonso-Martín J; Escudier-Villa JM; Tarín N; Cristóbal C; Sanz P; Pello AM; Aceña Á; Carda R; Orejas M; Tomás M; Beltrán P; Calero Rueda M; Marcos E; Serrano-Antolín JM; Gutiérrez-Landaluce C; Jiménez R; Cabezudo J; Curcio A; Peces-Barba G; González-Parra E; Muñoz-Siscart R; González-Casaus ML; Lorenzo A; Huelmos A; Goicolea J; Ibáñez B; Hernández G; Alonso-Pulpón LM; Farré J; Lorenzo Ó; Mahíllo-Fernández I; Egido J BMJ Open; 2016 Aug; 6(8):e011287. PubMed ID: 27496232 [TBL] [Abstract][Full Text] [Related]
13. Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. Yang R; Liu A; Ma X; Li L; Su D; Liu J J Cardiovasc Pharmacol; 2008 Apr; 51(4):396-401. PubMed ID: 18427283 [TBL] [Abstract][Full Text] [Related]
14. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study. Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004 [TBL] [Abstract][Full Text] [Related]
15. Sodium Tanshinone IIA sulfonate for acute myocardial infarction: a systematic review and Meta-analysis. Lian B; Zeng R; Chen Y; Liao P; Guo L; Zhang M J Tradit Chin Med; 2021 Feb; 41(1):26-35. PubMed ID: 33522194 [TBL] [Abstract][Full Text] [Related]
16. Exploration of Multiple Signaling Pathways Through Which Sodium Tanshinone IIA Sulfonate Attenuates Pathologic Remodeling Experimental Infarction. Mao S; Vincent M; Chen M; Zhang M; Hinek A Front Pharmacol; 2019; 10():779. PubMed ID: 31354493 [TBL] [Abstract][Full Text] [Related]
17. Elevated end-diastolic wall stress after acute myocardial infarction predicts adverse cardiovascular outcomes and longer hospital length of stay. Mosleh W; Elango K; Shah T; Chaudhari M; Gandhi S; Kattel S; Karki R; Khalil C; Frodey K; Dahal S; Okeeffe C; Aljebaje Z; Nagahama M; Punnanithinont N; Sharma UC Echocardiography; 2018 Nov; 35(11):1721-1728. PubMed ID: 30220086 [TBL] [Abstract][Full Text] [Related]
18. Impact of Left Ventricular vs Biventricular Pacing on Reverse Remodelling: Insights From the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial. Skaf S; Thibault B; Khairy P; O'Meara E; Fortier A; Vakulenko HV; Pitre C; White M; Ducharme A; Can J Cardiol; 2017 Oct; 33(10):1274-1282. PubMed ID: 28941607 [TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Achilli F; Malafronte C; Lenatti L; Gentile F; Dadone V; Gibelli G; Maggiolini S; Squadroni L; Di Leo C; Burba I; Pesce M; Mircoli L; Capogrossi MC; Di Lelio A; Camisasca P; Morabito A; Colombo G; Pompilio G; Eur J Heart Fail; 2010 Oct; 12(10):1111-21. PubMed ID: 20861135 [TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA prevents left ventricular remodelling via the TLR4/MyD88/NF-κB signalling pathway in rats with myocardial infarction. Wu DM; Wang YJ; Han XR; Wen X; Li L; Xu L; Lu J; Zheng YL J Cell Mol Med; 2018 Jun; 22(6):3058-3072. PubMed ID: 29524303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]